Immunomodulation using genetically engineered bacteria for type III-mediated delivery of heterologous antigens and cytokines: Potential application in vaccine and therapeutical developments

Immunopharmacology and Immunotoxicology

Volumn 32, Issue 1, 2010, Pages 1-4

  Chamekh, Mustapha ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Immunomodulation; Therapeutic; Type III mediated delivery; Vaccine

Indexed keywords

ANTIGEN; BACTERIAL VACCINE; CANCER ANTIBODY; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT INTERLEUKIN 10;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; BACTERIUM; DRUG DELIVERY SYSTEM; DRUG EFFICACY; ENTAMOEBA HISTOLYTICA; ENTERITIS; GENETIC ENGINEERING; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATORY DISEASE; NONHUMAN; PLASMODIUM BERGHEI; PRIORITY JOURNAL; REVIEW; SALMONELLA TYPHIMURIUM; YERSINIA ENTEROCOLITICA;

ANIMALS; ANTIGENS, HETEROPHILE; BACTERIA; CANCER VACCINES; CYTOKINES; GENETIC ENGINEERING; HUMANS; IMMUNOMODULATION; INFLAMMATION; VACCINES, SYNTHETIC;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; PSEUDOMONAS; SALMONELLA; SHIGELLA; YERSINIA;

EID: 77249157810     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923970902817890     Document Type: Review

References (51)

1. McConnel MJ, Imperiale MJ. Biology of adenovirus and its use as a vector for gene therapy. Hum Gene Ther 2004;15(11):1022-1033.
2. Dormond E, Perrier M, Kamen A. From the first to the third generation adenoviral vectors: what parameters governing the production yield. Biotech Adv 2008.
3. Grillot-Courvalin C, Goussard S, Courvalin P. Bacteria as gene delivery vectors for mammalian cells. Curr Opin Biotech 1999;10:477-481.
4. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. J Pathol 2006;208:290-298.
5. Scott CC, Botelho RJ, Grinstein S. Phagosome maturation: a few bugs in the system. J Membr Biol 2003;193(3):137-152.
6. Dulcos S, Desjardins M. Subversion of young phagosome: the survival strategies of intracellular pathogens. Cell Microbiol 2000;2(5):365-377.
7. Pizarro-Cerdà J, Cossart P. Subversion of cellular functions by Listeria monocytogenes. J Pathol 2006;208(2):215-223.
8. Cornelis GR. The type III secretion injectisome. Nat Rev Microbiol 2006;4:811-825.
9. Parsot C. Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors. FEMS Microbiol Lett 2005;252(1):11-18.
10. Galàn JE, Wolf-Watz H. Protein delivery into eukaryotic cells by type III secretion machines. Nature 2006;444(7119):567-573.
11. Williams MA, Bevan MJ. Effector and memory CTL differentiation. Ann Rev Immunol 2007;25:171-192.
12. Titball RW. Vaccines against intracellular bacterial pathogens. Drug Discov Today 2008;13(13-14):596-600.
13. Good MF, Stanisic D, Xu H, Elliott S, Wykes M. The immunological challenge to developing a vaccine to the blood stages of malaria parasites. Immunol Rev 2004;201:254-267.
14. Von Stebut E, Udey MC. Requirement for Th1-dependant immunity against infection with Leishmania major. Microbes Infect 2004;6(12):1102-1109.
15. Chamekh M. CD40-CD40L interaction in immunity against protozoan infections. J. Biomed Biotech 2007;1-6.
16. Verhoeven D, Teijaro JR, Farber DL. Heterogeneous memory T cells in anti-viral immunity and immunopathology. Viral Immunol 2008;21(2):99-113.
17. Kennedy R, Celis E. Multiple role for CD4 positive cells in antitumor immune vaccine. Immunol Rev 2008;222:129-144.
18. Gomez CE, Nàjera JL, Krupa M, Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccine against infectious diseases and cancer. Curr Gene Ther 2008;8(2):97-120.
19. Ferreira TB, Alves PM, Aunins JG, Carrondo MJ. Use of adenoviral vectors as veterinary vaccines. Gene Ther 2005;12:73-83.
20. Reyers-Sandoval A, Harty JT, Todryk SM. Viral vectors vaccines make memory T cells against malaria. Immunology 2007;121(2):158-165.
21. Glover DJ, Lipps HJ, Jans DA. Toward safe, non viral therapeutic gene expression in humans. Nature Rev Genet 2005;6:299-310.
22. Takeda K, Akira S. Toll-like receptors in innate immunity. Intern Immunol 2005;17(1):1-14.
23. Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006;442:39-44.
24. Darji A, Guzman CA, Gerstel B, Wachholz P, Timmis KN, Wehland J et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 1997;91(6):765-775.
25. Rüssmann H, Shams H, Poblete F, Fu Y, Galan JE, Donis RP. Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 1998;281:565-568. (Pubitemid 28357372)
26. Panthel K, Meinel KM, Sevil Domènech VE, Trülzsch K, Rüssmann H. Salmonella type III-mediated heterologous antigen delivery: A versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Intern J Med Microbiol 2008;298:99-103.
27. Evans DT, Chen LM, Gillis J, Lin KC, Harty B, Mazzara GP et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol 2003;77(4):2400-2409.
28. Rüssmann H, Igwe EI, Sauer J, Hardt WD, Bubert A, Geginat G. Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J Immunol 2001;167:357-365.
29. Kotton CN, Lankowski AJ, Scott N, Sisul D, Chen LM, Raschke K et al. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella type III secretion system. Vaccine 2006;24:6216-6224.
30. Tartz S, Rüssmann H, Kamanova J, Sebo P, Sturm A, Heussler V et al. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid. Vaccine 2008;26(47):5935-5944.
31. Lotter H, Rüssmann H, Heesemann J, Tannich E. Attenuated recombinant Yersinia as live oral vaccine carrier to protect against amoebiasis. Intern J Med Microbiol 2008;298:79-86.
32. Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y et al. In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest 2006;116:1946-1954.
33. Panthel K, Meinel KM, Sevil Domènech VE, Geginat G, Linkemann K, Busch DH et al. Prophylactic anti-tumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system. Microbes Infect 2006;8:2539-2546.
34. Epaulard O, Derouazi M, Margerit C, Marlu R, Filopon D, Polack B et al. Optimization of a type III secretion system-based Pseudomonas aeruginosa live vector for antigen delivery. Clin Vaccine Immunol 2008;15(2):308-313. (Pubitemid 352025536)
35. O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowiks C. Strategies for use of IL-10 or its antagonist in human disease. Immunol Rev 2008;223:114-131.
36. Herfarth HH, Mohanty SP, Rath HC, Tonkonogy S, Sartor RB. IL-10 suppresses experimental chronic, granulomatous inflammation induced by bacterial cell wall polymers. Gut 1996;38:836-845.
37. Arend WP. IL-1 receptor antagonist. Adv Immunol 1993; 54:167-227.
38. Cominelli F, Nast CC, Duchini A, Lee M. Recombinant interleukin- 1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis. Gastroenterology 1992;103:65-77.
39. Van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous IL-10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997;133:383-389.
40. Schreiber S, Fedoral RN, Nielsen OH, Wild J, Williams CN, Nikolaus S et al. Safety and efficacy of recombinant human IL-10 in chronic active Crohn's disease: Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000;119:1461-1472.
41. Fedorak RN, Gangl A, Elson CO, Rutqeerts P, Schreiber S, Wild J et al. Recombinant human IL-10 in the treatment of patients with mild to moderately active Crohn's disease: the IL-10 inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000; 119:1473-1482.
42. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W et al. Treatment of murine colitis by Lactococcus lactis secreting IL-10. Science 2000;289:1352-1355.
43. Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ. Local delivery of adenoviral vectors encoding murine IL-10 induces colonic IL-10 production and is therapeutic for murine colitis. Gut 2003;52:981-987. (Pubitemid 36765290)
44. Chamekh M, Phalipon A, Quertainmont R, Salmon, I, Sansonetti P, Allaoui A. Delivery of biologically active anti-inflammatory cytokines IL-10 and IL-1ra in vivo by the Shigella type III secretion system. J Immunol 2008;180(6):4292-4298.
45. D'hauteville H, Khan S, Maskell DJ, Kussak A, Weintraub A, Mathison J, Ulevitch RJ, Wuscher N, Parsot C, Sansonetti PJ. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 2002;168:5240-5251.
46. Zychlinsky A, Sansonetti PJ. Apoptosis as a proinflammatory event: what can we learn from bacteria-induced cell death? Trends Microbiol 1997;5:201-204.
47. Arondel J, Singer M, Matsukawa A, Zychlinsky A, Sansonetti PJ. Increased IL-1 and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental shigellosis. Infect Immun 1999;67:6056-6066.
48. Andus T, Daig R, Vogel D. Imbalance of the IL-1 system in colonic mucosa: association with intestinal inflammation and IL-1 receptor antagonist genotype 2. Gut 1997;41:651-657.
49. Coster TS, Hoge CW, Van De Verg LL, Hartman AB, Oaks EV, Venkatesan MM et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999;67:3437-3443.
50. Singer M, Sansonetti PJ. IL-8 is a key chemokine regulating neutrophil recruitment in a new mouse model of Shigella-induced colitis. J Immunol 2004;173(6):4197-4206.
51. Fernandez MI, Thuizat A, Pedron T, Neutra M, Phalipon A et al. A newborn mouse model for the study of intestinal pathogenesis of shigellosis. Cell Microbiol 2003;5(7):481-491.